언어 선택

FITC

FITC 제품 목록

속성
Antibody (1)
제품 라이브러리
온라인 (1)
종
Rabbit (1)
태그
- (1)
마커
Acridinium ester Labeled (1)

제품 번호	종	발현 시스템	제품 설명	단백질 구조	순도	특성
FIC-S288	Rabbit	HEK293	Anti-FITC Antibody, Rabbit IgG-Acridinium ester (F11) (MALS verified)

총 수량1

FITC분자 배경

Chemiluminescence immunoassay (CLIA) is a much more effective measurement with the advantages of high sensitivity, uniformity and broad dynamic range. However, in traditional chemiluminescent immunoassay (CLIA),microplate was applied to immobilize antigen or antibody by physical absorption, which holds a negative effect on the perfor-mance of assay because of the low specific surface area of micro-plate. The use of micromagnetic particles (MMPs) have proven to be a support for addressing the shortage of traditional CLIA mentioned above The chemiluminescent immunoassay is a technique used for disease diagnosis, drug development, chemical reaction monitoring, and many other applications. The MMPs-based chemiluminescence immunoassays could improve the surface area for immobilization, capture efficiency and accuracy of the assay, thus obtaining higher sensitivity and shorter analysis time.

임상 약물 정보

영어 이름	연구 코드	연구 개발 단계	회사	적응증	임상 시험
Zanzalintinib	XL-092	Phase 3 Clinical	Exelixis Inc	Solid tumours; Leiomyosarcoma; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Carcinoma, Transitional Cell; Prostatic Neoplasms, Castration-Resistant; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular	상세
Sitravatinib	MGCD-516; IND-155305; MGCD-0516; MG-91516; MG-516	Phase 3 Clinical		Breast Neoplasms; Gastrointestinal Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular; Endometrial Neoplasms; Lung Neoplasms; Metastatic breast cancer; Esophageal Squamous Cell Carcinoma; Mouth Neoplasms; Carcinoma, Squamous Cell; Hepatic Insufficiency; Ureteral Neoplasms; Solid tumours; Lung Diseases; Liposarcoma; Uveal melanoma; Triple Negative Breast Neoplasms; Carcinoma, Transitional Cell; Neoplasms; Carcinoma; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Kidney Neoplasms; Biliary Tract Neoplasms	상세
MRX-2843	UNC-2371; UNC-2025; MRX-2843	Phase 2 Clinical	University Of North Carolina At Chapel Hill	Leukemia; Solid tumours; Neoplasms; Pathologic Processes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lung Neoplasms; Leukemia, Myeloid, Acute; Neoplastic Processes; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung	상세
Merestinib	5OGS5K699E; LY-2801653	Phase 2 Clinical	Eli Lilly And Company	Biliary Tract Neoplasms; Skin Melanoma; Bone metastases; Solid tumours; Neoplasms; Pancreatic Neoplasms; Microsatellite instability-high cancer; Lymphoma, Mantle-Cell; Breast Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Gallbladder Neoplasms; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung	상세
Adrixetinib	Q-702	Phase 2 Clinical	Vichem Chemie, Max Planck Institute of Biochemistry, Lead Discovery Center GmbH	Erdheim-Chester Disease; Uterine Cervical Neoplasms; Central Nervous System Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Metastasis; Carcinoma, Hepatocellular; Lymphoma; Lymphoma, T-Cell, Cutaneous; Waldenstrom Macroglobulinemia; Leukemia, Myeloid, Acute; Primary Myelofibrosis; Histiocytic Sarcoma; Lymphoma, T-Cell, Peripheral; Histiocytosis, Langerhans-Cell; Lymphoma, Follicular; Histiocytosis, Sinus; Neoplasms; Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic; Esophageal Neoplasms; Leukemia, Lymphoid; Stomach Neoplasms; Solid tumours; Hematologic Neoplasms	상세
INCB-081776	INCB-81776; INCB-081776	Phase 1 Clinical	Incyte Corp	Solid tumours; Squamous Cell Carcinoma of Head and Neck	상세
NPS-1034	HOPE-777; KDDF-201111-02		Neopharma Ltd		상세

시판 약물 정보

영어 이름	연구 코드	연구 개발 단계	회사	가장 빠른 브랜드 이름	가장 빠른 승인 국가	가장 빠른 적응증	가장 빠른 승인 회사	가장 빠른 승인 날짜	적응증	임상 시험
Cabozantinib S-malate	XL-184; BMS-907351; RO7047650; RO-7047650	Approved	Exelixis Inc	Cometriq, Cabometyx	United States	Thyroid Neoplasms; Carcinoma, Neuroendocrine	Exelixis Inc	2012-11-29	Neuroblastoma; Thyroid Neoplasms; Hepatic Insufficiency; Astrocytoma; Peritoneal Neoplasms; Bile Duct Neoplasms; Colorectal Neoplasms; Gliosarcoma; Urethral Neoplasms; Sarcoma, Clear Cell; Uterine Neoplasms; Cholangiocarcinoma; Neurofibroma, Plexiform; Brain Neoplasms; Adenocarcinoma, Clear Cell; Carcinoma, Adenosquamous; Medullary thyroid cancer (MTC); Sarcoma, Ewing; Sarcoma; Osteosarcoma; Sarcoma, Alveolar Soft Part; Neoplasm Metastasis; Melanoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Endometrioid; Thyroid Cancer, Papillary; Meningioma; Paraganglioma; Neoplasms, Germ Cell and Embryonal; Carcinoma, Hepatocellular; Prostatic Neoplasms; Glioma; Brain metastases; Endometrial Neoplasms; Leukemia, Myeloid, Acute; Carcinoma, Squamous Cell; Lymphoma; Carcinoma, Neuroendocrine; Fallopian Tube Neoplasms; Carcinoma, Renal Cell; Adenoma, Islet Cell; Glioblastoma; Carcinoma, Ovarian Epithelial; Renal Insufficiency; Hepatoblastoma; Pheochromocytoma; Carcinoid Tumor; Carcinoma, Merkel Cell; Rejection of liver transp	상세